drugset / Trial / NCT04130828

Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia

NCT04130828

RandomizedParallel-groupOpen-labelTreatment

Summary

Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency and Iron deficiency anemia can present with a multitude of symptoms including fatigue, dyspnea on exertion, dysphagia, pallor, palpitations, headaches, tinnitus, taste disturbance and pica. Oral iron supplementation is associated with increasing hemoglobin in multiple studies in women, pregnant women and elderly patients. However, the optimal dose and frequency of oral iron supplementation for treatment remains unclear. The current proposed study attempts to address this gap in the literature.

Timeline

Start
2020-01-21
Primary completion
2022-01-18
Completion
2022-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferrous Sulfate Diagnostic / imaging agent 200 mg Oral